CSTL News and Press, Castle Biosciences Inc.

FRIENDSWOOD, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data evaluating DecisionDx-Melanoma’s i31-SLNB test result for prediction of sentinel lymph ...

FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 20...

2026-02-26 20:58:41 ET More on Castle Biosciences Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript Castle Biosciences Q4 2025 Earnings Preview Seeking Alpha’s Quant Rating on Castle Biosciences Historical earnings data for Castle Biosci...

2026-02-26 20:57:54 ET Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call February 26, 2026 4:30 PM EST... Read the full article on Seeking Alpha For further details see: Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript

2026-02-26 18:03:41 ET Image source: The Motley Fool. Feb. 26, 2026 at 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-26 16:22:26 ET More on Castle Biosciences Castle Biosciences Q4 2025 Earnings Preview Seeking Alpha’s Quant Rating on Castle Biosciences Historical earnings data for Castle Biosciences Financial information for Castle Biosciences Read...

2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE)...

Evertec Inc. (EVTC) is expected to report $0.81 for Q4 2025 BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $0.06 for Q4 2025 FTI Consulting Inc. (FCN) is expected to report $1.38 for Q4 2025 Arbe Robotics Ltd. (ARBE) is expected to report $-0.1 for Q4 2025 Aclaris Ther...

FRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a prospective, multicenter clinical validation study in the  Journal of the American ...

FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the clo...